Trailing twelve months where a flow is involved, latest reported balance where it is not.
Soft Tissue Repair Products is 89% of revenue.
Year to Dec 31, 2025 · $103.1M
Quarter to Jun 30, 2025 · $25.8M
No yearly breakdown — showing the quarter
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
$111.91MQ3 2026+1.9%
Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.
$8.7MQ3 2026-23.2%
Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.
-$3.02MQ3 2026+90.6%-2.7% of revenue
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
-2.7%Q3 2026+90.8%
How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.
$7.29MQ3 2026+61.9%
Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.
-$3.72Q2 2026+4.6%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.
8.55MQ3 2026-0.5%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.
$200KQ1 2021
Cash handed to shareholders. A flat line at zero means the company pays none. Each quarter on its own, so seasonal highs and lows are visible.
Everything above comes from Sanara Medtech Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Share-count jumps we cannot explain: 1.92x around Dec 31, 2017, 0.01x around Dec 31, 2019, and 2.69x around Dec 31, 2020. No split accounts for these, so nothing was adjusted — most often it is real dilution rather than a data problem, which is why it is flagged and not corrected.
Not reported by this filer: Interest Income, Non-interest Income, Non-interest Expense, Deposits, Short-term Investments, Short-term Borrowings, Share Repurchases, Change in Customer Advances, Change in Other Operating Capital, and Change in Working Capital. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
SMTI · Nasdaq · Healthcare · Medical Instruments and Supplies
$32.35-0.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 12, 2026
Company outlook: revenue of $110M to $115M for Fiscal year 2026 — up 9.1% on a year earlier